文献速递神经免疫帕金森病与运动障碍

抗mGluR1脑炎的临床特征、预后因素及抗体效应

Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis.
PubMed 文献 · Neurology · 2020-09-14

该研究纳入11例新发和19例既往报道的抗mGluR1脑炎患者(共30例,中位年龄55岁),主要临床表现为亚急性小脑综合征,常伴行为/认知改变或其他神经症状。随访25例中13例(52%)临床稳定、10例(40%)显著改善、2例死亡;2年预后不良者病情高峰时共济失调评分更差且更常需辅助行走。抗体主要为IgG1,可使培养神经元mGluR1簇显著减少。

要点

  • 抗mGluR1脑炎以亚急性小脑综合征为主要表现,常伴行为/认知改变。
  • 2年预后不良者病情高峰时共济失调更重、更常需辅助行走。
  • 抗体主要为IgG1,可致培养神经元mGluR1簇显著减少。

核心结论

  • 抗mGluR1脑炎表现为严重小脑综合征,常导致长期残疾和小脑萎缩。
  • 抗mGluR1抗体具有致病性,可使培养神经元mGluR1簇显著减少。

研究设计与样本

  • 回顾性分析11例新发和19例既往报道的抗mGluR1脑炎患者,共30例,中位年龄55岁。
  • 采用脑免疫组化和基于细胞的检测法测定mGluR1抗体及IgG亚类,并在大鼠海马神经元上研究抗体对mGluR1簇的影响。

主要发现

  • 30例中25例(86%)除小脑综合征外伴有行为/认知改变或其他神经症状。
  • 26例中3例(11%)发现肿瘤;19例中7例(37%)起病时脑MRI异常,12例中10例(83%)随访时显示小脑萎缩。
  • 30例中25例(83%)接受免疫治疗;随访25例中13例(52%)临床稳定、10例(40%)显著改善、2例死亡。
  • 2年预后不良(改良Rankin量表评分>2,n=7)者病情高峰时共济失调评估与评分量表评分更差且更常需辅助行走。
  • 抗mGluR1抗体主要为IgG1,可使培养神经元mGluR1簇显著减少。

临床怎么用

  • 对亚急性小脑综合征伴行为/认知改变者应检测抗mGluR1抗体。
  • 病情高峰时共济失调严重度和行走辅助需求有助于识别远期预后不良者。

局限性

  • 部分分析基于既往报道病例,新发病例仅11例。
  • 随访信息仅25例可获得,预后因素分析样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clinically characterize patients with anti-metabotropic glutamate receptor (mGluR) 1 encephalitis, to identify prognostic factors, and to study the immunoglobulin G (IgG) subclasses and effects of antibodies on neuronal mGluR1 clusters. METHODS: Clinical information on new and previously reported patients was reviewed. Antibodies to mGluR1 and IgG subclasses were determined with brain immunohistochemistry and cell-based assays, and their effects on mGluR1 clusters were studied on rat hippocampal neurons. RESULTS: Eleven new patients were identified (10 adults, 1 child);4 were female. In these and 19 previously reported cases (n = 30, median age 55 years), the main clinical manifestation was a subacute cerebellar syndrome that in 25 (86%) patients was associated with behavioral/cognitive changes or other neurologic symptoms. A tumor was found in 3 of 26 (11%). Brain MRI was abnormal in 7 of 19 (37%) at onset and showed cerebellar atrophy in 10 of 12 (83%) at follow-up. Twenty-five of 30 (83%) patients received immunotherapy. Follow-up was available for 25: 13 (52%) had clinical stabilization; 10 (40%) showed significant improvement; and 2 died. At the peak of the disease, patients with bad outcome at 2 years (modified Rankin Scale score > 2, n = 7) were more likely to have higher degree of initial disability, as reflected by a worse Scale for Assessment and Rating of Ataxia score, and more frequent need of assistance to walk. Antibodies to mGluR1 were mainly IgG1 and caused a significant decrease of mGluR1 clusters in cultured neurons. CONCLUSIONS: Anti-mGluR1 encephalitis manifests as a severe cerebellar syndrome, often resulting in long-term disability and cerebellar atrophy. The antibodies are pathogenic and cause significant decrease of mGluR1 clusters in cultured neurons.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Spatola M, Petit Pedrol M, Maudes E, et al. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology. 2020. PMID: 32928978. doi:10.1212/WNL.0000000000010854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。